Abstract
Ropivacaine is a new amide local anaesthetic, which is the first commercially available in its category as a pure S-(-) enantiomer. In most recent studies [40], ropivacaine exhibited a very close pharmacodynamic profile to equipotent doses of bupivacaine. Concentrations of 0.5percent, 0.75percent and 1percent (5, 7.5 and 10 mg / mL, respectively) ropivacaine are used for intraoperative anaesthesia, while the concentration of 0.2percent (2 mg / mL) is preferred for postoperative analgesia, either alone or in combination with opioids and / or clonidine. Ropivacaine is responsible for excellent postoperative analgesia following epidural and peripheral perineural injections, using single-shot injections and continuous infusions. Differential sensory / motor block is only apparent at low concentrations (0.2percent and less). A significant amount of recent literature focuses on its use for peripheral blocks of the lower limbs, i.e. sciatic and femoral nerve blocks. The primary benefit of ropivacaine is its lower toxicity, mainly lower cardiotoxicity, following accidental intravascular injection. This higher therapeutic index leads to an improved safety profile as compared with potent local anaesthetics such as racemic bupivacaine. For that reason, ropivacaine is a good choice for both intraoperative and postoperative regional anaesthesia and analgesia.
Keywords: Ropivacaine, local anaesthetic, Epidural Administration, LOWER LIMB SURGERY, Sciatic Nerve Blocks, Postoperative Analgesia
Current Topics in Medicinal Chemistry
Title: Clinical Application of Ropivacaine for the Lower Extremity
Volume: 1 Issue: 3
Author(s): Jean-Jacques Eledjam, Jacques Ripart and Eric Viel
Affiliation:
Keywords: Ropivacaine, local anaesthetic, Epidural Administration, LOWER LIMB SURGERY, Sciatic Nerve Blocks, Postoperative Analgesia
Abstract: Ropivacaine is a new amide local anaesthetic, which is the first commercially available in its category as a pure S-(-) enantiomer. In most recent studies [40], ropivacaine exhibited a very close pharmacodynamic profile to equipotent doses of bupivacaine. Concentrations of 0.5percent, 0.75percent and 1percent (5, 7.5 and 10 mg / mL, respectively) ropivacaine are used for intraoperative anaesthesia, while the concentration of 0.2percent (2 mg / mL) is preferred for postoperative analgesia, either alone or in combination with opioids and / or clonidine. Ropivacaine is responsible for excellent postoperative analgesia following epidural and peripheral perineural injections, using single-shot injections and continuous infusions. Differential sensory / motor block is only apparent at low concentrations (0.2percent and less). A significant amount of recent literature focuses on its use for peripheral blocks of the lower limbs, i.e. sciatic and femoral nerve blocks. The primary benefit of ropivacaine is its lower toxicity, mainly lower cardiotoxicity, following accidental intravascular injection. This higher therapeutic index leads to an improved safety profile as compared with potent local anaesthetics such as racemic bupivacaine. For that reason, ropivacaine is a good choice for both intraoperative and postoperative regional anaesthesia and analgesia.
Export Options
About this article
Cite this article as:
Eledjam Jean-Jacques, Ripart Jacques and Viel Eric, Clinical Application of Ropivacaine for the Lower Extremity, Current Topics in Medicinal Chemistry 2001; 1 (3) . https://dx.doi.org/10.2174/1568026013395317
DOI https://dx.doi.org/10.2174/1568026013395317 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Artificial intelligence for Natural Products Discovery and Development
Our approach involves using computational methods to predict the potential therapeutic benefits of natural products by considering factors such as drug structure, targets, and interactions. We also employ multitarget analysis to understand the role of drug targets in disease pathways. We advocate for the use of artificial intelligence in predicting ...read more
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
SV40 and HIV Sequences in the Cerebrospinal Fluid of a Patient with AIDS Dementia Complex
Current HIV Research Targeted Multimodal Liposomes for Nano-delivery and Imaging: An Avenger for Drug Resistance and Cancer
Current Gene Therapy Withdrawal Notice: MMR Vaccine Susceptibility of Viral Agents Causing Meningitis and Meningoencephalitis in Children
Infectious Disorders - Drug Targets Withdrawal Notice: Neuroprotective Effect of Lithospermum officinale callus Extract on Inflamed Primary Microglial Cells
Current Pharmaceutical Biotechnology Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy Clear Shot at Primary Aim: Susceptibility of Trypanosoma cruzi Organelles, Structures and Molecular Targets to Drug Treatment
Current Topics in Medicinal Chemistry Opportunities and Challenges in Nano-structure Mediated Drug Delivery: Where Do We Stand?
Current Nanomedicine How to Make a Non-Antigenic Protein (Auto) Antigenic: Molecular Complementarity Alters Antigen Processing and Activates Adaptive-Innate Immunity Synergy
Anti-Cancer Agents in Medicinal Chemistry New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets Update on Clinical, Pathophysiological and Therapeutic Aspects in ANCAAssociated Vasculitides
Current Drug Discovery Technologies Increasing Access to HIV Testing for Women by Simplifying Pre- and Post-Test Counseling
Current Women`s Health Reviews Nerve Injury Associated with Regional Anesthesia
Current Topics in Medicinal Chemistry Maternal Sepsis: Current Approaches to Recognition and Clinical Management
Current Women`s Health Reviews Eph/ephrin Signaling as a Potential Therapeutic Target After Central Nervous System Injury
Current Pharmaceutical Design IgG4 Related Syndrome: Another Multiorgan Disease in the Interest Field of Internal Medicine
Current Pharmaceutical Design Oral Tolerance and TGF-β -Producing Cells
Inflammation & Allergy - Drug Targets (Discontinued) Overcoming Chondroitin Sulphate Proteoglycan Inhibition of Axon Growth in the Injured Brain: Lessons from Chondroitinase ABC
Current Pharmaceutical Design The Blood-Brain Barrier: Targeting in the Pathogenesis of C. neoformans Meningitis and Drug Discovery
Anti-Infective Agents PEGylated Liposomal Vancomycin: A Glimmer of Hope for Improving Treatment Outcomes in MRSA Pneumonia
Recent Patents on Anti-Infective Drug Discovery Eight Stranded β -Barrel and Related Outer Membrane Proteins: Role in Bacterial Pathogenesis
Protein & Peptide Letters